Lab Information
Waqqas Afif (MD/MSc)
InvestigatorClinical Research Unit
Department of Medicine (McGill)
Research Profile
Keywords
Inflammatory bowel disease • Crohn's disease • ulcerative colitis • biologic medications • therapeutic drug monitoringResearch Interests
My research focuses on the safety and efficiency of biologic medications in the treatment of IBD. I am interested in the use of therapeutic drug monitoring to optimize the treatment of IBD patients on biologic medications.Team Members
| Name | Position |
|---|
Latest Publications
- Pedicelli, A. & Afif, W. (2024). In active ulcerative colitis, risankizumab induced and maintained remission. Annals of internal medicine, vol. 177, p. JC127.
- Bacsur, P., Resál, T., Sarlós, P., Iliás, Á., Dalma Sümegi, L., Kata, D., Dávid, A., Farkas, B., Ivány, E., Bálint, A., Bősze, Z., Fábián, A., Bor, R., Szepes, Z., Afif, W., Bessissow, T., Farkas, K., Lakatos, P. L. & Molnár, T. (2024). Outcomes of treatment cessation after switching to subcutaneous vedolizumab treatment in inflammatory bowel diseases. Therapeutic advances in gastroenterology, vol. 17, p. 17562848241290636.
- Birck, M. G., Lukusa, L., Choquette, D., Boire, G., Maksymowych, W. P., Singh, H., Afif, W. & Bernatsky, S. (2024). Incidence of serious infection among etanercept and infliximab initiators: safety comparison between biosimilars and bio-originators with Canadian population-based data. BMC rheumatology, vol. 8, p. 47.
- Seow, C. H., Marshall, J. K., Stewart, E., Pettengell, C., Ward, R. & Afif, W. (2024). The relationship among vedolizumab drug concentrations, biomarkers of inflammation, and clinical outcomes in a Canadian real-world study. Journal of the Canadian Association of Gastroenterology, vol. 7, p. 290-298.
- Jairath, V., Afif, W., Bressler, B., Pope, J. E., Selchen, D., Targownik, L. E. & Panaccione, R. (2024). Practical guidance for managing patients with moderate-to-severe ulcerative colitis using small molecule therapies. Journal of the Canadian Association of Gastroenterology, vol. 7, p. 282-289.
- Bacsur, P., Wetwittayakhlang, P., Resál, T., Földi, E., Vasas, B., Farkas, B., Rutka, M., Bessissow, T., Afif, W., Bálint, A., Fábián, A., Bor, R., Szepes, Z., Farkas, K., Lakatos, P. L. & Molnár, T. (2024). Accuracy of the Pancolonic Modified Mayo Score in predicting the long-term outcomes of ulcerative colitis: a promising scoring system. Therapeutic advances in gastroenterology, vol. 17, p. 17562848241239606.
- Afif, W., Arasaradnam, R. P., Abreu, M. T., Danese, S., Sandborn, W. J., Miao, Y., Zhang, H., Panaccione, R., Hisamatsu, T., Scherl, E. J., Leong, R. W., Rowbotham, D. S., Peyrin-Biroulet, L., Sands, B. E. & Marano, C. (2024). Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-term Maintenance Study. The American journal of gastroenterology, vol. 119, p. 910-921.
- Wetwittayakhlang, P., Karkout, K., Wongcha-Um, A., Tselekouni, P., Al-Jabri, R., Afif, W., Wild, G., Bitton, A., Bessissow, T. & Lakatos, P. L. (2024). Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with inflammatory bowel disease: A prospective observational study. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, vol. 56, p. 35-42.
- Gorodensky, J. H., Bernatsky, S., Afif, W., St-Pierre, Y., Filion, K. B. & Vinet, É. (2023). Assessing Serious Infections in Children Exposed In Utero to Ustekinumab. The Journal of rheumatology.
- Al-Jabri, R. & Afif, W. (2023). In moderately to severely active UC, etrasimod increased remission at 12 and 52 wk but increased adverse events. Annals of internal medicine, vol. 176, p. JC82.
See also
